Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring <i>POLE</i> exonuclease domain mutation.

Wen, Lei; Chen, Zhigang; Ji, Xiaomeng; Fong, William Pat; Shao, Qiong; Ren, Chao; Cai, Yanyu; Li, Binkui; Yuan, Yunfei; Wang, Deshen; Li, Yuhong

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation.

Wen, Lei; Chen, Zhigang; Ji, Xiaomeng; Fong, William Pat; Shao, Qiong; Ren, Chao; Cai, Yanyu; Li, Binkui; Yuan, Yunfei; Wang, Deshen; Li, Yuhong.

Afiliación

Wen L; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yatsen University Cancer Center, Guangzhou, Guangdong, China.
Chen Z; Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou, China.
Ji X; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yatsen University Cancer Center, Guangzhou, Guangdong, China.
Fong WP; Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou, China.
Shao Q; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yatsen University Cancer Center, Guangzhou, Guangdong, China.
Ren C; Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou, China.
Cai Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yatsen University Cancer Center, Guangzhou, Guangdong, China.
Li B; Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou, China.
Yuan Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yatsen University Cancer Center, Guangzhou, Guangdong, China.
Wang D; Department of Molecular Diagnostics, Sun Yatsen University Cancer Center, Guangzhou, China.
Li Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yatsen University Cancer Center, Guangzhou, Guangdong, China.

J Immunother Cancer ; 10(7)2022 07.

Article en En | MEDLINE | ID: mdl-35793867

Asunto(s)

Neoplasias Colorrectales; ADN Polimerasa II; Neoplasias Hepáticas; Proteínas de Unión a Poli-ADP-Ribosa; Neoplasias Colorrectales/tratamiento farmacológico; Neoplasias Colorrectales/genética; Neoplasias Colorrectales/metabolismo; Neoplasias Colorrectales/patología; ADN Polimerasa II/genética; ADN Polimerasa II/metabolismo; Humanos; Inhibidores de Puntos de Control Inmunológico/farmacología; Neoplasias Hepáticas/tratamiento farmacológico; Neoplasias Hepáticas/genética; Neoplasias Hepáticas/metabolismo; Neoplasias Hepáticas/secundario; Mutación; Proteínas de Unión a Poli-ADP-Ribosa/genética; Proteínas de Unión a Poli-ADP-Ribosa/metabolismo; Estudios Retrospectivos

Palabras clave

Biomarkers, Tumor; Gastrointestinal Neoplasms; Immunotherapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / ADN Polimerasa II / Proteínas de Unión a Poli-ADP-Ribosa / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google